Tesamorelin

Overview

Tesamorelin is a synthetic analog of growth hormone-releasing hormone consisting of the full 44-amino acid GHRH sequence stabilised with a trans-3-hexenoic acid modification at the N-terminus. It is the only GHRH analog to receive FDA approval, sanctioned in injectable form for HIV-associated lipodystrophy (excess visceral adipose tissue).

Research Context

The clinical evidence base for Tesamorelin is more developed than most research peptides in this catalogue, given its pathway through regulatory approval. Phase 3 trials documented significant and selective reductions in visceral adipose tissue (VAT) with preserved lean mass, alongside improvements in lipid profiles and quality-of-life measures. Post-marketing research has continued to explore applications in metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), and cognitive function in older adults, where IGF-1 elevation may confer neuroprotective benefit. It produces a more physiological GH pulse pattern than direct GH administration.

Oral Capsule Format

Tesamorelin’s 44-amino acid length makes it one of the larger peptides in the catalogue and presents a challenging oral delivery target. Biohacker’s encapsulation system addresses this through a multi-layer enteric polymer coating and a validated permeation-enhancer matrix designed for larger GHRH-class peptides.

2mg per capsule  ·  60 capsules per bottle. Every batch independently tested for purity, mass confirmation, and endotoxin compliance. Certificate of Analysis available for each lot.

For research purposes only. Not for human or veterinary use.